EUVIMEDEUVIMED entdecken
Crossref

The Molecular Mechanism by which LINC00461 Regulates Carfilzomib Resistance in Multiple Myeloma

Lifang Cheng, Fanjuan Zhang

The Tohoku Journal of Experimental Medicine · 2025

DOI: 10.1620/tjem.2024.j082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Tohoku Journal of Experimental Medicine, 2025. Verfasst von Lifang Cheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Shenshan Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. Hauptthemen laut MEDLINE: Multiple Myeloma, Drug Resistance, Neoplasm, Oligopeptides, RNA, Long Noncoding. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is a frequent haematological malignancy of the bone marrow. Carfilzomib, a first-line treatment for MM, has excellent antitumour effects, but its efficacy eventually decreases due to primary or acquired chemoresistance. Therefore, the regulatory mechanism of carfilzomib resistance has attracted much attention for improving the survival outcomes of patients with MM. By using database analysis combined with quantitative real-time polymerase chain reaction (qRT‒PCR), aberrant lncRNAs in MM were screened in carfilzomib-resistant cells versus carfilzomib-sensitive cells, and the resistance index of cultured carfilzomib-resistant cells was analysed compared to that of parental cells. Furthermore, cell viability, proliferation, and apoptosis in response to treatment with carfilzomib were measured after treatment with LINC00461 by the cell counting kit-8 (CCK-8) method and flow cytometry. The expression of LINC00461 was also verified through qRT‒PCR. Then, the possible miRNA molecules on which LINC00461 may act were investigated by RNA immunoprecipitation (RIP) and dual-luciferase reporter assays. Next, tumorigenesis in mice was evaluated to verify the effect of LINC00461 on carfilzomib-resistant cells. Increased expression of LINC00461 was related to drug resistance in MM patients. Mechanistically, LINC00461 overexpression attenuated the effect of miR-539-3p overexpression and decreased the expression of the downstream protein RAB5A. Moreover, compared with the control group, the LINC00461 knockdown group treated with carfilzomib exhibited decreases in tumour volume and weight. Furthermore, LINC00461 sensitized carfilzomib-sensitive cells by promoting the release of exosomes. These data suggest that LINC00461 plays an important role in the development of carfilzomib resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaDrug Resistance, NeoplasmOligopeptidesRNA, Long NoncodingHumansAnimalsCell Line, TumorGene Expression Regulation, NeoplasticCell ProliferationApoptosisMiceCell SurvivalMicroRNAsCarcinogenesisFemaleXenograft Model Antitumor AssaysMale

Stichwörter der Autor:innen

LINC00461RAB5Acarfilzomib resistancemiR-539-3pmultiple myeloma

Substanzen

carfilzomibOligopeptidesRNA, Long NoncodingMicroRNAs

Autor:innen und Institutionen

  • Department of Haematology, Shenshan Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University.
  • Department of Emergency, Shenzhen Samii Medical Center.

Zitieren

APA

Cheng, L., & Zhang, F. (2025). The Molecular Mechanism by which LINC00461 Regulates Carfilzomib Resistance in Multiple Myeloma. The Tohoku Journal of Experimental Medicine. https://doi.org/10.1620/tjem.2024.j082

Vancouver

Cheng L, Zhang F. The Molecular Mechanism by which LINC00461 Regulates Carfilzomib Resistance in Multiple Myeloma. The Tohoku Journal of Experimental Medicine. 2025. doi:10.1620/tjem.2024.j082

BibTeX
@article{Cheng2025,
  author = {Cheng, Lifang and Zhang, Fanjuan},
  title = {The Molecular Mechanism by which LINC00461 Regulates Carfilzomib Resistance in Multiple Myeloma},
  journal = {The Tohoku Journal of Experimental Medicine},
  year = {2025},
  doi = {10.1620/tjem.2024.j082}
}
Kostenlos starten →